Featured Publications
661. Ibalizumab Efficacy and Safety Through 48 Weeks of Treatment: Results of an Expanded Access Protocol (TMB-311)
Emu B, DeJesus E, Berhe M, Leider J, Creticos C, Weinheimer S, Cohen Z. 661. Ibalizumab Efficacy and Safety Through 48 Weeks of Treatment: Results of an Expanded Access Protocol (TMB-311). Open Forum Infectious Diseases 2019, 6: s303-s303. PMCID: PMC6811265, DOI: 10.1093/ofid/ofz360.729.Peer-Reviewed Original ResearchTreatment-emergent adverse eventsWeeks of treatmentCopies/mLViral loadCopies/Cohort 2Multidrug-resistant HIV-1 infectionDay 0HIV-1 RNA levelsImmune reconstitution inflammatory syndromeLog10 copies/mLHIV-1 viral loadPivotal phase 3 studiesCohort 2 patientsDurable viral suppressionMajor eligibility criteriaReconstitution inflammatory syndromeWeek 24 visitCD4 cell countMedian viral loadTreatment-experienced patientsCells/mm3Phase 3 studyInjection site reactionsLog10 copies/
2023
Impact of Head and Neck Cancer Treatment on CD4 T Cell Decline and Recovery in People with HIV
Hicks D, Salahuddin S, Wu M, Perez-Irizarry J, Emu B, Park H. Impact of Head and Neck Cancer Treatment on CD4 T Cell Decline and Recovery in People with HIV. International Journal Of Radiation Oncology • Biology • Physics 2023, 117: e588. DOI: 10.1016/j.ijrobp.2023.06.1934.Peer-Reviewed Original ResearchCells/mm3CD4 countPercentage of baselineMann-Whitney testCD4 T-cell declineMedian baseline CD4 countMedian nadir CD4 countCancer treatmentBaseline CD4 countCancer treatment initiationMedian baseline CD4Treatment-related immunosuppressionNadir CD4 countMajority of patientsRetrospective chart reviewTime of diagnosisStart of treatmentT-cell declineNeck cancer treatmentMATERIAL/METHODSNonparametric Mann-Whitney testBaseline CD4Immunologic declineMedian CD4Antiretroviral therapy